United Therapeutics Co. (UTHR) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 42.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,407 shares of the biotechnology company’s stock after selling 11,246 shares during the period. GSA Capital Partners LLP’s holdings in United Therapeutics were worth $1,806,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new stake in United Therapeutics during the second quarter worth about $5,256,000. Comerica Bank boosted its holdings in United Therapeutics by 1.3% during the second quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock worth $4,635,000 after buying an additional 458 shares in the last quarter. River & Mercantile Asset Management LLP purchased a new stake in United Therapeutics during the second quarter worth about $908,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in United Therapeutics by 2.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock worth $15,959,000 after buying an additional 2,762 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new position in United Therapeutics during the second quarter worth about $925,000.

United Therapeutics Co. (NASDAQ:UTHR) opened at $137.41 on Friday. The firm has a market cap of $5,940.00, a P/E ratio of 11.97 and a beta of 1.42. United Therapeutics Co. has a 52-week low of $112.01 and a 52-week high of $169.89.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. During the same period in the previous year, the firm earned $4.23 earnings per share. United Therapeutics’s revenue was up 9.1% compared to the same quarter last year. research analysts anticipate that United Therapeutics Co. will post 12.45 earnings per share for the current fiscal year.

In other United Therapeutics news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total transaction of $78,137.60. Following the completion of the sale, the director now directly owns 1,555 shares in the company, valued at $209,489.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $128.95, for a total transaction of $160,026.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,411 shares of company stock valued at $2,601,966. 7.80% of the stock is owned by insiders.

A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. TheStreet cut shares of United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Cowen restated a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a research report on Friday, October 27th. HC Wainwright restated a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research report on Thursday, October 26th. Finally, BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. United Therapeutics has a consensus rating of “Hold” and a consensus target price of $136.10.

TRADEMARK VIOLATION NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/17/united-therapeutics-co-uthr-shares-sold-by-gsa-capital-partners-llp.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply